Adverse events · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events compared with stereotactic radiosurgery (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · Patients with brain metastases
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Cediranib plus chemotherapy showed no clear difference in serious adverse events compared with placebo plus chemotherapy (low certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib plus lapatinib showed no clear difference in serious adverse events compared with lapatinib (low certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib showed no clear difference in serious adverse events compared with lapatinib (low certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher serious adverse events compared with chemotherapy (moderate certainty).
1 finding from 1 review
Adverse events (severe) · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events (severe) compared with stereotactic radiosurgery (very low certainty).
1 finding from 1 review
Adverse events (moderate) · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events (moderate) compared with stereotactic radiosurgery (very low certainty).
1 finding from 1 review
Adverse events (moderate) · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events (moderate) compared with stereotactic radiosurgery plus WBRT (very low certainty).
1 finding from 1 review
Adverse events – musculoskeletal · weight reduction in obesity to improve survival in women with endometrial cancer
It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes adverse events – musculoskeletal compared with usual care compared to placebo (very low certainty).
1 finding from 1 review
Specific adverse events: haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether pazopanib plus lapatinib changes specific adverse events: haemorrhage compared with lapatinib (very low certainty).
1 finding from 1 review
Specific adverse events: haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether pazopanib changes specific adverse events: haemorrhage compared with lapatinib (very low certainty).
1 finding from 1 review
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib plus lapatinib probably leads to higher specific adverse events: hypertension compared with lapatinib (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Pazopanib probably leads to higher specific adverse events: hypertension compared with lapatinib (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: hypertension compared with chemotherapy (moderate certainty).
1 finding from 1 review
Serious adverse events (range of outcomes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in serious adverse events (range of outcomes) compared with laparotomy (low certainty).
1 finding from 1 review
Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious haemorrhage compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Specific adverse events: serioushypertension · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serioushypertension compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy may leads to higher specific adverse events: serious haemorrhage compared with chemotherapy (low certainty).
1 finding from 1 review
Adverse events: thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether pazopanib plus lapatinib changes specific adverse events: thromboembolic events compared with lapatinib (very low certainty).
1 finding from 1 review